TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01010477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray
Description: minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Nasal Spray
Description: minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Description: Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral counseling
Description: Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
Study: NCT03647735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-controlled sedation
Description: Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled sedation
Description: Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
Study: NCT03606941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture treatment
Description: Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture treatment
Description: Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery.
Study: NCT03771157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shingrix vaccine
Description: On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
Study: NCT02089581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator MR2XXX
Description: comparison of two new oral formulations with existing formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRXXX
Description: MRXXX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR1XXX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRXXX and MR1XXX
Description: MRXXX and MR1XXX in fed and fasted state
Study: NCT02631421

Intervention type: PROCEDURE
Intervention: Blood Sampling

Intervention type: PROCEDURE
Intervention: Blood Sampling

Intervention type: OTHER
Intervention: Cardiac MRI
Study: NCT04397523

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
Study: NCT02556905

Intervention type: DRUG
Intervention: REVLIMID®
Description: The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.

Intervention type: DRUG
Intervention: Dexamethasone
Description: The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
Study: NCT02934360

Intervention type: DEVICE
Intervention: TR(ACE) Assay Testing
Description: Serial plasma testing with TR(ACE) Assay

Intervention type: DEVICE
Intervention: TR(ACE) Assay Testing
Description: Serial plasma testing with TR(ACE) Assay
Study: NCT03022240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ametop
Description: Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ametop
Description: Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
Study: NCT01128218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor fluorescence
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2
Study: NCT03022240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
Study: NCT02696330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
Study: NCT03781115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ziprasidone
Description: anti-psychotic drug proposed for use as rapid diagnostic tool

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: anti-psychotic drug proposed for use as rapid diagnostic tool

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: anti-psychotic drug proposed for use as rapid diagnostic tool

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: anti-psychotic drug proposed for use as rapid diagnostic tool

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: A non drug oral placebo capsule will be given as a control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A non drug oral placebo capsule will be given as a control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: A non drug oral placebo capsule will be given as a control
Study: NCT00773955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01275196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Study: NCT01248962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
Study: NCT01287637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early reversal of temporary ileostomy
Description: Temporary ileostomy is reversed 8-13 days after the primary surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard reversal of temporary ileostomy
Description: Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
Study: NCT01827254

Intervention type: OTHER
Intervention: sunitinib: observational study
Description: Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
Study: NCT02910986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written educational brochure
Description: Written educational brochure about breast density

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written educational brochure
Description: Written educational brochure about breast density

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotora interaction
Description: Promotora education about breast density
Study: NCT02636894

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Silk
Study: NCT04004572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAP regimen
Description: Patients will be given LEAP regimen every 3 weeks for 8 cycles.
Study: NCT04524572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motion sensor
Description: To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motion sensor
Description: To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motion sensor
Description: To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
Study: NCT02508766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plantar stimulation
Description: The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
Study: NCT05924282

Intervention type: PROCEDURE
Intervention: Curative intent surgery
Description: Curative intent surgery means that surgeons intend to perform R0 resection.

Intervention type: PROCEDURE
Intervention: Curative intent surgery
Description: Curative intent surgery means that surgeons intend to perform R0 resection.
Study: NCT02810730

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pancreatic MRI
Description: Pancreatic MRI in the 6 months following the first consultation
Study: NCT01292174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibalizumab (biologic/MAb) for SC Injection or placebo
Description: ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibalizumab (biologic/MAb) for SC Injection or placebo
Description: ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibalizumab (biologic/MAb) for SC Injection or placebo
Description: ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
Study: NCT01128218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor fluorescence
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor fluorescence
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor fluorescence
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor fluorescence
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor fluorescence
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2
Study: NCT04357912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Tracker Group
Description: In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
Study: NCT04361513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)
Description: 3 point genicular nerve block

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)
Description: 3 point genicular nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)
Description: intra-articular injection of triamcinilone
Study: NCT04357912

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: Participants will receive standard of care exercise education.
Study: NCT02817516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-828 placebo-matching solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-828 placebo-matching solution.
Study: NCT01916603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative Intervention
Description: Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
Study: NCT00878150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person Cognitive Behavioral Therapy
Description: 12 sessions of CBT delivered in-person over 16 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Cognitive Behavioral Therapy
Description: 12 sessions of telephone-based CBT over 16 weeks
Study: NCT03238885

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic MR examination
Description: All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
Study: NCT00635453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Advice
Description: The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
Study: NCT01301781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801
Description: BLI801 laxative - oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BLI801 placebo - oral solution
Study: NCT03521297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: UDCA combined probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: UDCA combined placebo
Study: NCT00731757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira
Description: 80 mg at week 0, then 40 mg weekly from week 1-week 23.
Study: NCT01843114

Intervention type: DEVICE
Group type: OTHER
Intervention: FDOCT
Description: Measurement of retinal blood velocities

Intervention type: DEVICE
Group type: OTHER
Intervention: FDOCT
Description: Measurement of retinal blood velocities

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Vessel Analyzer
Description: Measurement of retinal vessel diameters

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Vessel Analyzer
Description: Measurement of retinal vessel diameters
Study: NCT04412200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen chamber (HBOC)
Description: HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
Study: NCT02533557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stimuplex insulated needle
Description: 2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimuplex insulated needle
Description: 2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine mixed with epinephrine
Description: 2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine mixed with epinephrine
Description: 2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
Study: NCT04543318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep temporal nerves
Description: Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massteric nerve
Description: group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
Study: NCT02863107

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood or saliva samples

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical charts

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04606992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CELS
Description: CELS resection for early colon cancer is a compromised resection performed in frail patients
Study: NCT04393064

Intervention type: DEVICE
Group type: OTHER
Intervention: fiberoptic endoscopic evaluation of swallowing
Description: intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera \& light source \& video recording system will be used. Procedure will be done without anesthesia~.
Study: NCT01668966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.